Avantor, Inc. (AVTR) Stock Price & How to Invest
Last updated July 2026
Short answer
Avantor (AVTR) is a global supplier of mission-critical products and services to the life sciences and advanced technology industries, so it functions as a diversified "picks and shovels" play on biopharma research and production rather than on any single drug. It is currently a turnaround story, with a new-look leadership team executing a "Revival" transformation program to restore growth and margins after several years of soft end markets.
AVTR stock price
As of 2026-07-17, Avantor, Inc. (AVTR) last closed at $11.07, down 16.7% over the past year. Over the past 52 weeks it has traded between $7.41 and $15.60.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Avantor, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Avantor, Inc. (AVTR) do?
Avantor, Inc. is a global provider of high-purity materials, consumables, equipment, and specialized services used across biopharma, healthcare, education, government, and advanced technology markets. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company sells everything from high-purity chemicals and reagents, lab supplies, and customized excipients to single-use assemblies, chromatography resins, and fluid handling systems. It reorganized around two reporting segments (Laboratory Solutions and a Bioscience and Medtech Products grouping), and a large share of its revenue is recurring consumables that customers reorder repeatedly, which gives the model a razor-and-blade quality tied to laboratory activity and biologic manufacturing volumes.
The investment picture as of July 2026 is dominated by a turnaround. Revenue slipped to roughly $6.55 billion in 2025 and organic sales were still declining modestly in early 2026 as biopharma customers stayed cautious on spending, yet Q1 2026 results beat expectations and the stock jumped, signaling early traction from the company's Revival cost and execution program. Avantor carries meaningful debt (net leverage above 3x adjusted EBITDA), so the equity behaves like a leveraged recovery play: if organic growth and margins inflect, the discounted valuation relative to larger tools peers offers upside, but if end markets stay weak the balance sheet limits room for error.
What's driving Avantor, Inc. (AVTR)?
1. Revival transformation program
Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. Q1 2026 results exceeded expectations partly on this self-help, and a new Chief Transformation Officer (Ludovic Brellier, hired from Danaher's Cytiva) was brought in to run the effort. Success here is the central swing factor for margins over the next several years.
2. Recurring consumables and bioprocessing exposure
A large portion of Avantor's sales are repeat-purchase consumables tied to ongoing lab and manufacturing activity rather than one-time capital equipment. Its Bioscience Production exposure (single-use assemblies, chromatography resins, excipients) links it to biologics and vaccine production, a structurally growing end market. This recurring base gives revenue relative stability once destocking and customer caution normalize.
3. End-market normalization
The soft patch across life sciences tools has been driven by post-pandemic inventory destocking and tighter biopharma and academic budgets. As those pressures ease, Avantor is positioned to return to organic growth. Management framed 2026 as a stabilization year, with organic revenue guided to roughly flat to slightly down and improvement expected as comparisons ease.
4. Free cash flow and deleveraging
Avantor generates substantial free cash flow (guided to roughly $500 million to $550 million for 2026), which it is directing toward reducing net leverage from above 3x adjusted EBITDA. Steady debt paydown would lower interest costs and financial risk, improving the equity's risk profile even before any strong top-line acceleration.
What are the risks to Avantor, Inc. (AVTR)?
Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (adjusted net leverage above 3x), which amplifies the downside if EBITDA disappoints and constrains flexibility. It reported GAAP net losses tied to write-downs, and the turnaround depends heavily on execution by a leadership team still being reshaped. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.
How is Avantor, Inc. (AVTR) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Avantor, Inc.'s investor relations page or your broker.
- Revenue (FY2025): ~$6.55B
- Q1 2026 net sales: ~$1.58B
- Q1 2026 adjusted EBITDA: ~$219M (~13.9% margin)
- 2026 adjusted EPS guide: ~$0.77 to $0.83
- Market cap: ~$5.7B
- Net debt / leverage: ~$3.6B (~3.2x adj. EBITDA)
As of July 2026 Avantor trades at a steep discount to larger life sciences tools peers, reflecting its slower growth, thinner margins, and higher leverage. The valuation embeds skepticism about the turnaround, so the stock tends to react sharply to signs of organic-growth inflection or margin recovery, as seen when shares jumped on the Q1 2026 beat. Figures are approximate and reference reported 2025 and Q1 2026 results.
Who competes with Avantor, Inc. (AVTR)?
Large diversified life sciences tools
Thermo Fisher Scientific, Danaher, and Agilent Technologies are far larger, better-capitalized rivals with broader product ranges and stronger margins. They compete directly across lab consumables, instruments, and bioprocessing, and their scale is a key reason Avantor trades at a valuation discount.
Bioprocessing and lab specialists
Merck KGaA (MilliporeSigma), Sartorius, and Bio-Rad Laboratories overlap with Avantor in chromatography, filtration, single-use bioprocessing, and specialty reagents. These players compete for the same biopharma production and research spending that drives Avantor's higher-margin Bioscience business.
Lab distribution and channel peers
As a distributor and channel partner through its VWR-rooted laboratory business, Avantor competes with other lab-supply distributors and e-commerce channels on breadth of catalog, service, and procurement efficiency, an area where it is investing to defend and grow share.
How to invest in Avantor, Inc. (AVTR)
There are three common ways to get AVTR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AVTR sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where AVTR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Avantor, Inc. (AVTR)
Investors treat AVTR as a leveraged, recovery-stage bet on a stabilizing life sciences tools market, where execution on the Revival program matters as much as the underlying demand backdrop.
More on Avantor, Inc. (AVTR)
Whether AVTR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AVTR a buy?, and where the stock could go from here in the AVTR stock forecast.
For income investors, whether AVTR pays a dividend and how the payout looks is covered in does AVTR pay a dividend?
Build a basket around AVTR with Walnut
Use Avantor, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Avantor do?
+
Avantor supplies mission-critical products and services to life sciences and advanced technology customers, including high-purity chemicals, reagents, lab supplies, excipients, single-use assemblies, chromatography resins, and specialized procurement and manufacturing services. Much of its revenue comes from recurring consumables used in laboratories and biologic production.
Is Avantor profitable?
+
Avantor generates positive adjusted EBITDA and free cash flow, and reported roughly $43 million of net income and about $219 million of adjusted EBITDA in Q1 2026. However, it also reported GAAP net losses in some recent periods tied to write-downs, so profitability depends on which measure you look at.
What is Avantor's Revival program?
+
Revival is a company-wide transformation initiative launched to cut costs, simplify the organization, and improve commercial and operational execution. A dedicated Chief Transformation Officer runs the Revival Management Office, and early results in Q1 2026 suggested the program was gaining traction.
Who are Avantor's main competitors?
+
Avantor competes with much larger life sciences tools companies such as Thermo Fisher Scientific, Danaher, and Agilent, plus bioprocessing and lab specialists like Merck KGaA (MilliporeSigma), Sartorius, and Bio-Rad. It also faces other lab-supply distributors in its channel business.
Why has Avantor's stock struggled?
+
Sales declined in 2024 and 2025 as biopharma and academic customers cut spending and worked down excess inventory after the pandemic. Combined with meaningful debt and thin margins, that weak top line pressured the stock, though a Q1 2026 earnings beat sparked a sharp rally.
How much debt does Avantor carry?
+
As of early 2026 Avantor reported roughly $3.6 billion of net debt and adjusted net leverage above 3x trailing adjusted EBITDA. The company is directing its free cash flow toward reducing that leverage over time, which is a key part of its recovery story.
What is Avantor's 2026 guidance?
+
For 2026 Avantor guided to organic revenue roughly flat to down a few percent, adjusted EPS of about $0.77 to $0.83, and free cash flow of roughly $500 million to $550 million. Management has framed 2026 as a stabilization year ahead of a potential return to growth.
How can someone invest in AVTR?
+
Avantor trades on the New York Stock Exchange under the ticker AVTR, so it can be bought like any US-listed stock through a brokerage account. It is a way to gain diversified exposure to life sciences research and biologic manufacturing without betting on a single drug or device. This is descriptive information, not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Avantor, Inc.'s investor relations page or your broker before making investment decisions.